Pharma & Biotech - Page 10

Merck (MRK) is pushing into one of the pharmaceutical industry’s most closely watched therapeutic categories with its newly developed oral cholesterol treatment, Lipfendra. The drug belongs to the PCSK9 inhibitor class, a

Amgen is pushing deeper into cardiovascular medicine as its cholesterol drug Repatha continues to gain ground following a significant regulatory milestone. The US Food and Drug Administration granted Repatha a label expansion

Gilead Sciences (GILD) has prevailed in a long-running legal battle after the California Supreme Court ruled in the company’s favour over its tenofovir-based HIV treatments. The decision brings years of complex litigation

Sandoz, the generics and biosimilars spinout of Novartis, has struck a pair of settlement agreements to resolve long-running antitrust litigation brought by US state and federal enforcers. The company announced it had

Amgen has disclosed a significant cybersecurity breach in which hackers stole sensitive patient health information and proprietary company data from its cloud systems. The California-based drugmaker identified unauthorised activity within cloud storage

Curium has agreed to acquire all outstanding shares of Lantheus Holdings (LNTH) in a transaction that could be worth as much as $8 billion. Under the terms of the deal, Lantheus shareholders

Otsuka has reported positive full results from its Phase 3 VISIONARY trial, showing its drug Voyxact stabilised kidney function in adults with IgA nephropathy over two years. Voyxact, known clinically as sibeprenlimab-szsi,

The pharmaceutical industry has reached a pivotal moment at the midpoint of 2026, shaped by an accelerating dealmaking environment and rapidly shifting patient access dynamics. A widening gap in patient affordability is

Supernus Pharmaceuticals and Indivior Pharmaceuticals have agreed to merge in an all-stock transaction creating a major central nervous system biopharmaceutical company. The combined entity will generate approximately $2.2 billion in annual revenue,

The Section 232 pharmaceutical tariff regime is no longer a looming threat for the industry — it is now active law following the July 31, 2026, deadline. President Trump’s April 2, 2026,